This question tests recognition of inadequate constipation prophylaxis in chronic opioid therapy. The patient is on scheduled extended-release oxycodone plus immediate-release for breakthrough pain but only has docusate (a stool softener) for constipation prevention. Chronic opioid use requires a stimulant laxative (like senna or bisacodyl) in addition to a stool softener for adequate bowel regimen. Option A is incorrect as combining long-acting and short-acting opioids is appropriate pain management. Option C is false as sertraline can be used with opioids. Option D suggests an inappropriate formulation change. The clinical pearl is that all patients on chronic opioids require both a stool softener AND a stimulant laxative; docusate alone is insufficient for opioid-induced constipation prevention.

This question assesses appropriate laboratory monitoring for aldosterone antagonists like spironolactone in patients with heart failure with reduced ejection fraction (HFrEF). The key patient-specific factors include the initiation of spironolactone at 25 mg daily alongside an ACE inhibitor (lisinopril), with baseline potassium at 4.9 mEq/L (upper normal limit) and serum creatinine at 1.3 mg/dL indicating potential renal impairment risk. Choice A is the best monitoring plan as it checks potassium and serum creatinine within 3–7 days, at 1 month, and periodically thereafter to detect hyperkalemia or worsening renal function early, which are common risks with this combination. Choice B is incorrect because the patient is not on warfarin, so INR monitoring for a spironolactone-warfarin interaction is irrelevant; choice C is suboptimal as spironolactone does not typically cause significant hyperglycemia requiring A1c checks in 2 weeks. Choice D is inappropriate because spironolactone requires routine monitoring due to its potassium-sparing effects, especially in HFrEF patients on renin-angiotensin system inhibitors. A transferable clinical pearl is that in heart failure management, aldosterone antagonists necessitate close electrolyte and renal function surveillance to prevent life-threatening complications like hyperkalemia. This framework involves tailoring monitoring frequency based on baseline labs and concurrent medications that affect potassium or renal clearance.

This question tests recognition of therapeutic duplication with anticoagulants. The patient is receiving both apixaban (a direct oral anticoagulant) and warfarin (a vitamin K antagonist) for atrial fibrillation, which represents dangerous duplication. Using two anticoagulants simultaneously significantly increases bleeding risk without additional benefit, as evidenced by the patient's low hemoglobin suggesting possible bleeding. Option A correctly identifies the need to stop one anticoagulant and continue monotherapy. Option B is incorrect because dual anticoagulation is not indicated for atrial fibrillation. Option C would further increase bleeding risk by adding antiplatelet therapy. Option D addresses a non-critical issue. The clinical pearl is that anticoagulant monotherapy is standard for atrial fibrillation; combining anticoagulants is rarely indicated and significantly increases bleeding risk.

This question tests knowledge of secondary stroke prevention after transient ischemic attack (TIA). The patient experienced a TIA 2 weeks ago and requires antiplatelet therapy for secondary prevention. Aspirin 81 mg daily is the first-line antiplatelet agent for secondary stroke prevention and is notably absent from her regimen. Clopidogrel 75 mg daily (option A) is an alternative first-line option but not superior to aspirin. Warfarin (option C) is not indicated for TIA without atrial fibrillation or other cardioembolic source. Dipyridamole/aspirin (option D) is an alternative but not preferred over aspirin monotherapy due to increased side effects. The clinical pearl is that all patients with TIA or ischemic stroke require antiplatelet therapy unless anticoagulation is indicated for another reason.

This question tests identification of therapeutic duplication with alpha-1 blockers. The patient is receiving both tamsulosin and doxazosin, which are both alpha-1 blockers used for benign prostatic hyperplasia (BPH). This duplication increases the risk of orthostatic hypotension, as evidenced by the patient's low blood pressure (102/64 mmHg). Using two alpha-1 blockers provides no additional benefit for BPH symptoms while significantly increasing adverse effects. Option B incorrectly suggests increasing sildenafil dose for urinary symptoms. Option C incorrectly relates diuretic choice to BPH. Option D contains false information about age contraindications. The clinical pearl is that combining alpha-1 blockers for BPH is inappropriate and increases hypotension risk; if monotherapy is inadequate, add a 5-alpha reductase inhibitor instead.

This question tests the ability to identify inappropriate dosing in chronic kidney disease. The patient has severe renal impairment with a creatinine clearance of 28 mL/min, requiring dose adjustment for renally eliminated medications. Sitagliptin requires dose reduction to 25 mg daily when CrCl is <30 mL/min to prevent drug accumulation and potential hypoglycemia. Metformin is contraindicated when eGFR <30 mL/min due to lactic acidosis risk, making option C incorrect. Atorvastatin does not require dose adjustment for renal impairment, making option D incorrect. The clinical pearl is to always calculate creatinine clearance and adjust doses of renally eliminated drugs accordingly, particularly DPP-4 inhibitors which accumulate in kidney disease.

This question tests recognition of therapeutic duplication in acid-suppressive therapy for GERD. The key patient-specific factor is concurrent omeprazole and pantoprazole, both PPIs, leading to hypomagnesemia and potential overuse without improved control. Using a single PPI and evaluating need is the best choice to reduce risks and costs. Stopping calcium carbonate ignores its antacid role, adding ranitidine adds redundancy, and switching to esomeprazole maintains duplication. These distractors perpetuate overlap or introduce unnecessary agents. A clinical pearl is that dual PPI therapy offers no benefit over single and increases adverse effects like hypomagnesemia or infections. In GERD management, de-escalate to the lowest effective dose or H2RA if possible, assessing symptoms periodically.

This question tests prophylaxis for opioid-induced constipation in chronic pain management. The key patient-specific factor is chronic opioid use without a laxative, increasing constipation risk in an elderly patient. Adding a stimulant or osmotic laxative like senna or polyethylene glycol is the best choice for effective prophylaxis. Docusate alone is often insufficient, loperamide would worsen constipation, and diphenhydramine has no role in motility. These distractors are ineffective or counterproductive for OIC. A clinical pearl is that all patients on scheduled opioids should receive prophylactic laxatives, preferring stimulants over stool softeners for OIC. Use a decision framework of assessing bowel regimen in opioid users and escalating to osmotics if stimulants fail.

This question tests recognition of teratogenic contraindications in pregnancy. The key patient-specific factor is the 10-week pregnancy, making lisinopril contraindicated due to fetal renal and cardiovascular risks. Recommending to stop lisinopril and contact the prescriber for a safer alternative like labetalol is the best choice for maternal-fetal safety. Continuing or reducing lisinopril exposes the fetus to harm, and adding potassium is irrelevant. These distractors prioritize BP over fetal risks inappropriately. A clinical pearl is that ACE inhibitors are pregnancy category D/X, requiring immediate discontinuation upon pregnancy confirmation. Use a framework of reviewing all medications for teratogenicity in reproductive-age women and switching to pregnancy-safe options promptly.

This question tests secondary prevention strategies after ischemic stroke. The key patient-specific factor is the history of ischemic stroke without atrial fibrillation, necessitating antiplatelet therapy for recurrence prevention. Adding aspirin 81 mg daily is the best choice as it reduces stroke risk by about 20% in non-cardioembolic cases. Rivaroxaban is not indicated without AF, clonidine lacks preventive evidence, and prednisone can increase vascular risks. These alternatives are inappropriate or harmful for secondary prevention. A clinical pearl is that aspirin monotherapy is first-line for secondary stroke prevention in non-AF patients, with dual therapy considered for high-risk cases. Use a decision framework of assessing stroke etiology (e.g., TOAST classification) to select antiplatelet vs. anticoagulant therapy.